Showing 3861-3870 of 5231 results for "".
- Study: Aerolase Neo Elite Laser Is as Effective as the Gold Standard Laser for Treating Psoriasishttps://practicaldermatology.com/news/study-aerolase-neo-elite-laser-is-as-effective-as-the-gold-standard-laser-for-treating-psoriasis/2460674/The efficacy and tolerance of the 650-microsecond 1064-nm Nd:YAG laser (Aerolase NeoElite) is equivalent to the excimer laser for the treatment of mild to moderate psoriasis vulgaris of the arms and legs, according to a new study in the Journal of Drugs in Dermatology.
- MyHealthTeams' "Gaining Control with Psoriasis" Challenge Empowers Psoriasis Patients to Change Things Uphttps://practicaldermatology.com/news/myhealthteams-gaining-control-with-psoriasis-challenge-empowers-psoriasis-patients-to-change-things-up/2460663/
- Dermatologists React to Reports of Adverse Events in Filler Patients Who Got COVID-19 Vaccineshttps://practicaldermatology.com/news/report-covid-19-vaccines-and-dermatology/2460648/As case reports of facial swelling in patients with a history of dermal filler treatment who received Moderna’s COVID-19 vaccine accrue, dermatologists are devising new protocols for how to best address this potential phenomenon, including the optimal timing of fillers and vaccines, updated
- Six Investigators to Receive NEA Grants for Eczema Researchhttps://practicaldermatology.com/news/six-investigators-to-receive-nea-grants-for-eczema-research/2460638/The
- Hydrafacial To Go Public After $1.1 Billion Dealhttps://practicaldermatology.com/news/hydrafacial-to-go-public-after-11-billion-deal/2460634/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa
- Almirall's Klisyri Gets FDA Approval for AKshttps://practicaldermatology.com/news/almiralls-klisyri-gets-fda-approval-for-aks/2460632/Almirall is expected to launch Klisyri® (tirbanibulin) for the topical treatment of actinic keratosis (AK) of the face or scalp in the first quarter of 2021, after receiving FDA approval this week. Klisyri® is a novel, topic
- Hoth Therapeutics Gets Greenlight to Start Phase 1b Trial of BioLexa for AD in Australiahttps://practicaldermatology.com/news/hoth-therapeutics-gets-greenlight-to-start-phase-1b-trial-of-biolexa-for-ad-in-australia/2460627/Hoth Therapeutics, Inc. received Human Research Ethics Committee clearance to commence the first cohort of the Phase 1b clinical trial of
- New Government Advisory Cites Risk for Ransomware Attacks on Healthcare Systemhttps://practicaldermatology.com/news/new-government-advisory-cites-risk-for-ransomware-attacks-on-healthcare-system/2460587/A new advisory coauthored by the Cybersecurity and Infrastructure Security Agency (CISA), the Federal Bureau of Investigation (FBI), and the Department of Health and Human Services (HHS) warns of the potential for ransomware attacks against hospitals and medical systems. “CI
- Sklice Goes Over-the-Counterhttps://practicaldermatology.com/news/sklice-goes-over-the-counter/2460581/Sklice (ivermectin) lotion, 0.5% is now approved for OTC sale. Sklice (Arbor Pharmaceuticals) was originally FDA approved as a prescription treatment for head lice infestation in patients six months of age and older in February 2012. “The Rx-t
- The HydraFacial Company And Circadia Expand Partner Boosters Globallyhttps://practicaldermatology.com/news/the-hydrafacial-company-and-circadia-expand-partner-boosters-globally/2460579/The HydraFacial Company is extending their partnership with Circadia to offer the Chrono-Peptide Booster and ProTec Plus Booster to HydraFacial providers in more than 40 countries. "The Circadia boosters for HydraFacial are already loved by providers and consume